GlassScriptPhysician profile
Elizabeth Mathew
NPI 1770711871
$2,812.63
in general payments reported to CMS, 2019-2025
35 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2022: $51.27 · 2023: $725 · 2024: $781 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $258.44 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $257.83 | 2019-2025 | Zepbound, Mounjaro, Synjardy |
| Pfizer INC. | $235.19 | 2023-2025 | |
| Astellas Pharma US INC | $175.56 | 2022-2025 | Veozah |
| Abbott Laboratories | $155.33 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $147.46 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $141.33 | 2024-2025 | |
| Axsome Therapeutics, INC. | $124.30 | 2025 | Auvelity |
| Exact Sciences Corporation | $114.98 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $113.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $106.45 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $94.36 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Medline Industries LP | $73.22 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $67.62 | 2023-2025 | Rexulti, Jynarque |
| Tris Pharma INC | $65.36 | 2023-2024 | Dyanavel Xr |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.